← Russell 3000 cross-section

EBS Emergent BioSolutions Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$296m
Revenue TTM
$770m
Net income TTM
$-177m
Free cash flow
$86m
Composite score
47.9
Sector rank
#2665

Valuation

P / E
EV / EBITDA
26.0
EV / sales
1.0
FCF yield
28.99%
Earnings yield vs 10-yr
-64.39pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-23.0%
EBITDA margin
3.7%
ROE
-51.8%
ROIC
-8.4%
Revenue growth
-9.6%

Insider activity, last 90 days

Net open-market
$-0.03m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

TSA revenue from the SERB TSA (RSDL ® divestiture) and Bora TSA (Baltimore-Camden facility divestiture, TSA no longer active in 2026) recognized during the three and six months ended June 30, 2026 was $ 0.8 million and $ 1.2 million, respectively. TSA revenue recognized during the three and six months ended June 30, 2025 was $ 0.7 million and $ 2.0 million, respectively. The following table summarizes the Company’s finite-lived intangible assets: Amortization expense associated with the Company’s finite-lived intangible assets was recorded as follows: 2026 Impairment of long-lived assets During the preparation and review of the financial statements for the quarter ended June 30, 2026, the Co …Emergent BioSolutions Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →